Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 416

Results For "AI"

8753 News Found

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
Drug Approval | January 23, 2024

EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome

GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023


European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
Clinical Trials | January 23, 2024

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union


Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
News | January 23, 2024

Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr

Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023


Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
News | January 23, 2024

Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr

Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023


Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr
News | January 22, 2024

Tatva Chintan Pharma Chem Q3 FY24 consolidated PAT drops to Rs. 3.45 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023


Novo Holdings expands portfolio in cancer diagnostics
News | January 22, 2024

Novo Holdings expands portfolio in cancer diagnostics

Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer


AbbVie launches Produodopa for treatment of parkinson's disease in EU
News | January 20, 2024

AbbVie launches Produodopa for treatment of parkinson's disease in EU

Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations


Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market
Drug Approval | January 19, 2024

Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market

Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets


Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
News | January 19, 2024

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator


NATCO invests US$ 2 million in Cellogen Therapeutics
News | January 18, 2024

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy